Biotechnology
13 companies under coverage.
Biotechnology
Vertex Pharmaceuticals Inc (VRTX)
SELL. 12-month probability-weighted target $466 (-15% vs spot). P/E Multiple explains 84% of Monte Carlo outcome variance.
United Therapeutics Corporation (UTHR)
HOLD. 12-month probability-weighted target $516 (+1% vs spot). P/E Multiple explains 86% of Monte Carlo outcome variance.
Repligen Corporation (RGEN)
SELL. 12-month probability-weighted target $126 (-31% vs spot). P/E Multiple explains 76% of Monte Carlo outcome variance.
Regeneron Pharmaceuticals Inc (REGN)
SELL. 12-month probability-weighted target $617 (-25% vs spot). P/E Multiple explains 80% of Monte Carlo outcome variance.
Neurocrine Biosciences Inc (NBIX)
HOLD. 12-month probability-weighted target $172 (+12% vs spot). P/E Multiple explains 71% of Monte Carlo outcome variance.
Incyte Corporation (INCY)
SELL. 12-month probability-weighted target $107 (-16% vs spot). P/E Multiple explains 78% of Monte Carlo outcome variance.
Halozyme Therapeutics Inc (HALO)
SELL. 12-month probability-weighted target $79 (-28% vs spot). P/E Multiple explains 88% of Monte Carlo outcome variance.
Gilead Sciences Inc (GILD)
SELL. 12-month probability-weighted target $122 (-17% vs spot). P/E Multiple explains 81% of Monte Carlo outcome variance.
Exelixis Inc (EXEL)
HOLD. 12-month probability-weighted target $57 (+4% vs spot). P/E Multiple explains 92% of Monte Carlo outcome variance.
Biomarin Pharmaceutical Inc (BMRN)
SELL. 12-month probability-weighted target $59 (-9% vs spot). P/E Multiple explains 78% of Monte Carlo outcome variance.
Biogen Inc (BIIB)
SELL. 12-month probability-weighted target $194 (-11% vs spot). P/E Multiple explains 68% of Monte Carlo outcome variance.
Amgen Inc (AMGN)
SELL. 12-month probability-weighted target $355 (-20% vs spot). P/E Multiple explains 80% of Monte Carlo outcome variance.
AbbVie Inc (ABBV)
HOLD. 12-month probability-weighted target $236 (-11% vs spot). P/E Multiple explains 84% of Monte Carlo outcome variance.